Content and data provided by various third parties and Fidelity − Terms of Use | Help/Glossary
Research > ETFs > ETF / ETP Commentary > 

Defiance CEO on Motivation Behind First Autism ETF

BY | ETF Database
10/16/2026 | 30 VIEWS
  • Related Symbols
  • ASD
Matthew Bielski, founder and CEO of Defiance ETFs, recently joined Scarlet Fu and Eric Balchunas on Bloomberg’s ETF IQ to discuss the Defiance Autism Impact ETF (ASD) and the personal family experience that helped inspire its development.Key Takeaways Personal experience inspired ASD. Bielski’s family experience helped drive the development of an ETF focused on companies serving the autism community. ASD targets a broad ecosystem. The fund invests across pharmaceuticals, diagnostics, behavioral health, specialized education and related services. The fund includes a philanthropic commitment. Defiance has pledged to donate 100% of ASD’s net advisory profits during its first two years and at least 50% thereafter to organizations supporting autism care, research and services. The Motivation Behind Launching the First Autism ETFFor Bielski, the idea for ASD was born out of a deeply personal journey. His son, Lev, now four years old, was diagnosed with severe autism. Navigating the daily reality of caring for a child with profound autism — from managing communication barriers and behavioral challenges to seeking out effective therapies — highlighted how underserved many families in the neurodivergent community truly are. While searching for answers, Bielski and his wife discovered promising emerging therapies. According to Bielski, his family learned that the drug had completed a Phase 2 clinical trial and that the company reported a 53% efficacy rate among children in the study. He subsequently said his family obtained expanded access to the treatment, allowing Lev to receive it outside the usual clinical-trial enrollment process. Bielski described the change he observed in his son as life-changing, particularly in terms of social engagement and affection. “Overnight he went from the least social kid, the least affectionate kid, to the most affectionate kid,” he said. See More: What Advisors Need to Know About the First Autism ETFWhat Investors Should Know About ASDDefiance launched ASD in June 2026. The fund tracks the VettaFi Autism Impact Index and holds roughly 40 companies. In addition, the index targets therapeutics, diagnostics, and educational technology. Top holdings include Revvity (RVTY), Teva Pharmaceutical (TEVA) and AbbVie (ABBV). ASD charges a 0.79% expense ratio. Currently, it manages approximately $1.35 million in assets. Defiance has pledged to donate 100% of ASD’s net advisory profits during its first two years and at least 50% thereafter to organizations supporting autism care, research and services. For more news, information, and analysis, visit the Thematic Investing Content Hub. VettaFi LLC (“VettaFi”) is the index provider for ASD for which it receives an index licensing fee. However, ASD is not issued, sponsored, endorsed, or sold by VettaFi, and VettaFi has no obligation or liability in connection with the issuance, administration, marketing, or trading of ASD.

More Commentary

Corporate Bonds Are More Alluring Than Meets the Eye
BY | ETF Database
10/16/2026 | 42 VIEWS
How TCAFs Research-Based Active ETF Approach Stands Out
BY | ETF Database
10/16/2026 | 43 VIEWS
Preference vs. Performance: Investing in ESG With RAFI Indices
BY | ETF Database
10/16/2026 | 34 VIEWS
View more Commentary

Search Commentary

Enter Keyword(s)
Filter Results

Performance data shown is past performance and is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore you have a gain or loss when you sell your shares. For standard quarterly performance, go to the fund's Snapshot page by clicking on the ETF/ETP's symbol.

ETFs may trade at a premium or discount to their NAV and are subject to the market fluctuations of their underlying investments.

For iShares ETFs, Fidelity receives compensation from the ETF sponsor and/or its affiliates in connection with an exclusive long-term marketing program that includes promotion of iShares ETFs and inclusion of iShares funds in certain FBS platforms and investment programs. Please note, this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral. Additional information about the sources, amounts, and terms of compensation can be found in the ETF's prospectus and related documents. Fidelity may add or waive commissions on ETFs without prior notice. BlackRock and iShares are registered trademarks of BlackRock, Inc. and its affiliates.

FBS receives compensation from the fund's advisor or its affiliates in connection with a marketing program that includes the promotion of this security and other ETFs to customers ("Marketing Program"). The Marketing Program creates incentives for FBS to encourage the purchase of certain ETFs. Additional information about the sources, amounts, and terms of compensation is in the ETF's prospectus and related documents. Please note that this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral.

News, commentary (including "Related Symbols") and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended to help self-directed investors evaluate exchange traded products (ETPs), including, but limited to exchange traded funds (ETFs) and exchange traded notes (ETNs). Criteria and inputs entered, including the choice to make ETP comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a particular security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating ETPs. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use. Determine which securities are right for you based on your investment objectives, risk tolerance, financial situation and other individual factors and re-evaluate them on a periodic basis.

Before investing in any exchange traded product, you should consider its investment objective, risks, charges and expenses. Contact Fidelity for a prospectus, offering circular or, if available, a summary prospectus containing this information. Read it carefully.